Tools for Practice

#210 Blazing Through the Evidence on THC Versus CBD Combinations in Medical Cannabinoids.

Do tetrahydrocannabinol (THC), cannabidiol (CBD), or the THC/CBD combination yield differing benefits or harms?

From four randomized controlled trials (RCT), one found THC/CBD superior to THC but this was inconsistent within study and with other studies. Adverse events are prevalent in THC/CBD and individual components. While some early poor-quality research in healthy users suggest CBD may attenuate some psychiatric effects of THC, better research in real patients is needed to verify any benefits of specific components.

CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

Join Now

Already a CFPCLearn Member? Log in

Identified four RCTs comparing THC, CBD, or combined. 
  • RCT: 243 terminal cancer and weight loss patients, comparing THC/CBD versus THC versus placebo over six weeks.1 
    • THC/CBD versus THC: No statistical difference in appetite or adverse events. 
  • RCT: 177 refractory cancer pain patients on strong opioids (~270 mg morphine), comparing THC/CBD versus THC versus placebo over two weeks.2 
    • 30% pain reduction38% THC/CBD versus 21% THC, Number Needed to Treat=6. 
      • No difference for ≥10% or ≥50% pain reduction. 
    • Adverse events: No difference with THC/CBD versus THC. 
  • RCT: 48 brachial nerve injury patients, comparing THC/CBD versus THC versus placebo over two weeks.3 
    • Baseline pain 7.5/10: Both THC/CBD and THC groups reduced pain ~1.3 points, statistically significantly more than 0.6 with placebo. 
    • Adverse events not significantly different between THC/CBD and THC. 
  • ‘N of 1’ RCT: 24 chronic pain patients who benefitted from THC/CBD, compared THC/CBD versus THC versus CBD versus placebo over eight weeks.4 
    • Patients reporting equal/better pain management versus original THC/CBD.   
      • 38% THC/CBD, 33% THC, 17% CBD: Not statistically different.  
  • RCT 120 Dravet syndrome pediatric patients: CBD reduced seizure frequency ~22% over placebo at 14 weeks.5 
    • Adverse events include somnolence (Number Needed to Harm (NNH)=4), diarrhea (NNH=5), and appetite loss (NNH=5). 
    • Recent RCT of lennox-gastaut (seizure) syndrome adults found similar.6  
  • Canadian guideline recommends cannabinoids only in refractory neuropathic pain, palliative cancer pain, chemotherapy-associated nausea/vomiting, and spasticity.7 
  • One guideline recommends low THC or high CBD:THC ratios to diminish THC adverse events.8 
    • Largely based on small studies of healthy volunteers (some with other drug use history) examining MRI or short-term scale changes.   

This content is certified for MainPro+ Credits, log in to access


  • Danielle Perry RN
  • G. Michael Allan MD CCFP
  • Joey Ton PharmD

1. Strasser F, Luftner D, Possinger L, et al. J Clin Oncol. 2006; 24(21):3394-400.

2. Johnson JR, Burnell-Nugent M, Lossignol D, et al. J Pain Symptom Manage. 2010; 39(2):167-79.

3. Berman J, Symonds C, Birch R. Pain. 2004; 112(3):299-306.

4. Notcutt W, Price M, Miller R, et al. Anaesthesia. 2004; 59(5):440-52.

5. Devinsky O, Cross JH, Laux L, et al. N Engl J Med. 2017; 376(21):2011-20.

6. Thiele EA, Marsh ED, French JA, et al. Lancet. 2018; 391:1085-96.

7. Allan GM, Ramji J, Perry D, et al. Can Fam Physician. 2018; 64(2):111-20.

8. Fischer B, Russell C, Sabioni P, et al. Am J Public Health. 2017 Aug; 107(8):1277.

Authors do not have any conflicts of interest to declare.